Who Paid My Doc
A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab
Research payments
$19,075,440
Through program year 2025, $19,075,440 in research payments was reported against A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab, across 1,116 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,375,917 | 167 |
| 2024 | Research | $1,682,078 | 114 |
| 2022 | Research | $5,746,537 | 302 |
| 2021 | Research | $5,621,056 | 258 |
| 2020 | Research | $4,649,852 | 275 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Noelle Cloven Fort Worth, TX Named on 77 payments
- Bhavana Pothuri New York, NY Named on 45 payments
- Michael Gold Tulsa, OK Named on 27 payments
- Evelyn Fleming Lebanon, NH Named on 26 payments
- Robert Holloway Orlando, FL Named on 24 payments
- Iwona Podzielinski Fort Wayne, IN Named on 15 payments
- Robert Morris Detroit, MI Named on 15 payments
- Eirwen Miller Pittsburgh, PA Named on 15 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.